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Abstract
Background: ET-743 (trabectedin, YondelisH) and PM00104 (ZalypsisH) are marine derived compounds that have antitumor
activity. ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug
resistance, but the mechanisms which lead to resistance are not yet understood.
Methodology/Principal Findings: Human chondrosarcoma cell lines resistant to ET-743 (CS-1/ER) or PM00104 (CS-1/PR)
were established in this study. The CS-1/ER and CS-1/PR exhibited cross resistance to cisplatin and methotrexate but not to
doxorubicin. Human Affymetrix Gene Chip arrays were used to examine relative gene expression in these cell lines. We
found that a large number of genes have altered expression levels in CS-1/ER and CS-1/PR when compared to the parental
cell line. 595 CS-1/ER and 498 CS-1/PR genes were identified as overexpressing; 856 CS-1/ER and 874 CS-1/PR transcripts
were identified as underexpressing. Three zinc finger protein (ZNF) genes were on the top 10 overexpressed genes list.
These genes have not been previously associated with drug resistance in tumor cells. Differential expressions of ZNF93 and
ZNF43 genes were confirmed in both CS-1/ER and CS-1/PR resistant cell lines by real-time RT-PCR. ZNF93 was overexpressed
in two ET-743 resistant Ewing sarcoma cell lines as well as in a cisplatin resistant ovarian cancer cell line, but was not
overexpressed in paclitaxel resistant cell lines. ZNF93 knockdown by siRNA in CS-1/ER and CS-1/PR caused increased
sensitivity for ET-743, PM00104, and cisplatin. Furthermore, ZNF93 transfected CS-1 cells are relatively resistant to ET-743,
PM00104 and cisplatin.
Conclusions/Significance: This study suggests that zinc finger proteins, and ZNF93 in particular, are involved in resistance
to ET-743 and PM00104.
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Introduction
ET-743 (YondelisH; Trabectedin) is marine alkaloid derivative
isolated from the Caribbean sea squirt Ecteinascidia turbinate [1,2].
ET-743 has a broad spectrum of activity in tumor cell lines at pM
and low nM concentrations, and it also has clinical activity
towards ovarian cancer, breast cancer, and sarcomas [2,3]. ET-
743 has been approved by the EMEA/EU for patients with
advanced sarcomas who have either progressed after treatment
with an anthracycline or are not clinically suitable to receive
conventional agents [4]. ET-743 is composed of three tetrahy-
droisoquinoline subunits containing a central carbinolamine
moiety enabling it to covalently bind to DNA. ET-743 binds to
the minor groove of the DNA helix with sequence-specific binding
preference for GC-rich triplets and subsequently forms covalent
adducts with the N2-position of guanine. As a result, the minor
groove is exposed and turned toward the major groove. When
such binding occurs, DNA strands become cross-linked and
cannot be replicated, resulting in cell death [5,6]. The direction of
DNA turning is a novel feature among DNA minor groove-
interactive agents, thus making ET-743 unique.
PM00104 (ZalypsisH), derived from mollusks, is a novel
chemical entity related to Jorumycin, a marine natural compound
belonging to the family of Renieramycins, obtained from sponges
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6967[7,8]. PM00104 has in vitro and in vivo anti-tumor activity towards a
wide variety of solid and hematological tumors. As with ET-743,
PM00104 also binds to DNA and is cytotoxic; however, unlike
ET-743, PM00104 does not activate the ‘‘DNA damage
checkpoint’’ response. Thus, the cytotoxic effects of PM00104,
although dependent on DNA binding, are not triggered by DNA
damage response mechanisms[8].
As with other chemotherapeutic drugs, ET-743 and PM00104
exposure over sustained periods of treatment will result in the
development of drug resistance, but the mechanisms are not well
understood. Different studies have reported conflicting descriptions
of the relationship between ABCB1 expression and ET-743
resistance in human cancer cell lines [9,10]. In the human ovarian
cell line IGROV-1, which is selected for ET-743 resistance, ABCB1
is overexpressed [11]. Sensitivity could be restored by the addition
of the Pgp1 inhibitor PSC-833, suggesting that ET-743 may be a
Pgp1 substrate. Another study however, observed that two Pgp
over-expressing human epidermoid cancer cell lines (KB-8-5 and
KB-C-2) were not resistant to ET-743 [9]. Notably, sub-lethal
concentrations of ET-743 could reverse resistance to doxorubicin
and vincristine in these cell lines. There are no reports describing
the mechanism of PM00104 resistance in tumor cells.
Chondrosarcomas are a heterogeneous group of tumors of
mesenchymal origin that develop in bone or cartilage and display
chondrocytic characteristics[12]. These tumors respond poorly to
conventional treatments such as chemotherapy and radiation, and
prognosis is related to tumor grade and differentiation status. The
sensitivity of sarcoma cells to ET-743 and PM00104 has led us and
others to consider these compounds as interesting candidates for
future treatment of chondrosarcoma [13,14,15]. However, as with
other chemotherapeutic agents, the propensity of tumor cells to
develop resistance to ET-743 or PM00104 poses a significant
challenge for using this drug over an extended period of time. The
goal of this study is to explore the mechanisms of ET-743 or
PM00104 resistance in chondrosarcoma.
Material and Methods
Chemotherapy drugs
ET-743 (YondelisH; Trabectedin) and PM00104 (ZalypsisH)
were supplied by PharmaMar (Spain). Paclitaxel (TaxolH),
Doxorubicin (Adriamycin RDFH, EC No. 2468183), Methotrex-
ate (Trexall) and Cisplatin (Cisplatinum; CDDP) were obtained
through unused residual clinical material provided by the
pharmacy at the Massachusetts General Hospital. The stock
solution of drugs were prepared according to the drug specifica-
tions and stored at 220uC.
Chondrosarcoma cell line CS-1
The human chonodrosarcoma cell line, propagated since 1999
and designated CS-1, were established from a surgically resected
human high grade chonodrosarcoma that was not previously
exposed to chemotherapy or radiation therapy, and grown in
monolayer. Briefly, tissue was aseptically obtained immediately
following resection, placed in RPMI-1640 tissue culture medium
supplemented with 10% fetal bovine serum, and the tissue
cultured at 37uC incubator containing 5% CO2 [13,14]. The
detailed analysis of CS-1 has been reported previously
[13,14,15,16,17]. Total RNA was extracted after CS-1 was
passaged four times.
Establishment of ET-743 or PM00104 resistant cell line
CS-1/ER and CS-1/PR cells resistant to ET-743 or PM00104
were established from the CS-1 parent cell line by exposure to ET-
743 or PM00104 with step-by step increase concentration of ET-
743 or PM00104 for one year using similar method as previously
reported [18,19,20]. In brief, cultured CS-1 cells were exposed to
0.00001 mM either ET-743 or PM00104 for 7 days and then
washed and cultured in medium containing 0.00003 mM for 7
days. If the CS-1 cells demonstrated cytotoxicities after exposure
to a given concentration of ET-743 or PM00104, they were
washed and cultured in drug-free medium for 7 days. For
example, we noticed 90% of CS-1 cells were killed when cells were
exposed to 0.001 mM of ET-743 or 0.003 mM of PM00104 for 7
days. When the viable cells had recovered, they were seeded in
medium containing the most recently exposed concentration of
drug again for 3 days. After repeated several cycles and when the
cells grew up to 70% confluence in the culture medium containing
drugs, the concentration of drugs will increased to the next level.
After one year, the ET-743 resistant cell line CS-1/ER and
PM00104 resistant cell line CS-1/PR were established as
determined by MTT assay. These cells represent populations of
drug resistant cells rather than a selected cloned population. CS-
1/ER can grow in concentrations of 0.005 mM ET-743 and CS-
1/PR can grow up in the concentration of 0.01 mM PM00104.
Other drug resistant cell line used in this study
Human ovarian cancer cell lines SKOV-3 and A2780 and a
human breast cancer cell line MCF-7 were purchased from
American Type Tissue Collection (Rockville, MD). The paclitaxel-
resistant SKOV-3TR, MCF-7TR and cisplatin-resistant A2780cp
cell lines were established as previously reported [19,20]. Dr.
Katia. Scotlandi (Institute Orthopedics Rizzoli, Italy) provided
Ewing sarcoma ET-743 resistant cell line TC-ET [21].
Tissue culture
All the cell lines were cultured in RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum, 100-
units/ml penicillin and 100 mg/ml streptomycin (Invitrogen). Cells
were incubated at 37uCi n5 %C O 2-95% air atmosphere and
passaged when near confluent monolayers were achieved using
trypsin-EDTA solution. Drug-resistant cell lines were periodically
cultured in the respective drug to confirm their drug resistance
characteristics. Cells were free on mycoplasma contamination as
tested by MycoAlert(R) Mycoplasma Detection Kit from Cambrex
(Rockland, ME).
Cytotoxicity assay
Drug cytotoxicity was assessed in vitro using the MTT assay as
previously described [22]. Briefly, 2610
3 cells per well were plated
in 96-well plates in culture medium (RPMI 1640 supplemented
with 10% fetal bovine serum and penicillin/streptomycin)
containing increasing concentrations of drug. After 7 days of
culture, 10 ml MTT (5 mg/ml in PBS, obtained from Sigma) were
added to each well and the plates were incubated for 4 h. The
resulting formazan product was dissolved with acid-isopropanol
and the absorbance at a wavelength of 490 nm (A490) was read on
a SPECTRAmaxH Microplate Spectrophotometer (Molecular
Devices, Sunnyvale, CA). The absorbance values were normalized
by assigning the value of the control line in the medium without
drug to 1.0 and the value of the no cell control to 0. Experiments
were performed in triplicate.
RNA extraction
Total RNA was collected from CS-1 (parental cell line with
passaged 4 times) , CS-1/ER and CS-1/PR ( resistant daughter cell
lines with cultured for one year) using TRIzolH Reagent (GIBCO,
ZNF93 and ET-743 Resistance
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account for and eliminate biologic noise, RNA was isolated from
three distinct flasks of each cell line. These biologic replicates were
pooled. RNA quality was determined via ethidium bromide staining
following agarose/formaldehyde gel electrophoresis.
Gene transcriptional profiling
Total RNA was processed and hybridized to Affymetrix Gene
Chip U133 Plus 2.0 arrays (Santa Clara, CA) by the Gene Array
Technology Center at Harvard Medical School (http://genome.
med.harvard.edu). Affymetrix Gene Chip U133 Plus 2.0 in the first
and most comprehensive whole human genome expression array.
This array completes coverage of the whole human Genome with
over 47,000 transcripts. Each probe consists of 20 separate 23-mer
oligonucleotides. The expression level of each mRNA is quantified
by measuring its hybridization to these 23-mers in comparison to its
hybridization to a one-base mismatch oligonucleotide.
Data analysis
GeneSifter was used to analyze the microarray data (http://
www.genesifter.net/web/). GeneSifter provides powerful analyti-
cal algorithms (RMA, PAM, ANOVA, CLARA, Benjamini-
Hochberg, etc.) through an intuitive web interface. GeneSifter
can identify differentially expressed genes and cluster analysis for
identifying patterns of gene expression and segregating genes
based on these patterns. Fold change in expression between
sensitive and resistant cell lines was evaluated using the Mann-
Whitney test. A tenfold or greater change in intensity combined
with a Mann-Whitney associated P value less than 0.05 was used
as the criterion for inclusion in our filtered data set. Intensity
information was exported to Microsoft Excel as needed.
TaqMan reverse transcription-PCR for quantification of
differentially expressed gene
Real-time RT-PCR were performed to validate differentially
expressed genes. For gene expression detection, cDNA reverse
transcription was performed from total RNA samples using specific
oligo dT primers from the Taq ManRNAAssays and reagents from
the TaqMan RNA Reverse Transcription kit (Applied Biosystems).
The resulting cDNA was amplified by PCR using Taq Man Zinc
finger protein 93 (ZNF93), ZNF43 and THADA gene assay primers
with the Taq Man Universal PCR Master Mix and analyzed with a
StepOnePlus Real time PCR System according to the manufactur-
er’s instructions (Applied Biosystems). GAPDH and actin were used
as a control. The relative levels of gene expression were calculated
from the relevant signals by normalization with the signal for
GAPDH oractin expression.PCRreactionmixturescontained Taq
Man human ZNF93, or ZNF43 and THADA and Universal PCR
Master Mix in a total volume of 20 AL. Cycling variables were as
follows: 95uC for 10 min followed by 40 cycles at 95uC (15 s) and
annealing/extension at 60uC (1 min). All reactions were performed
in triplicate.
ZNF93 siRNA assay
For ZNF93 (GenBank accession number: NM_031218) inter-
ference, sense ZNF93 oligo (59-CCUCUACCCUUAGUUCA-
CAtt-39) and antisense ZNF93 oligo (59-UGUGAACUAAGG-
GUAGAGGag-39) were purchased from Applied Biosystems and
was used according to the manufacturer’s instructions. For
validation of ZNF93 RNAi specificity, the siGenome SMARTpool
Human ZNF93 siRNAs were purchased from Dharmacon
(Chicago,IL) with the following four target sequences of ZNF93
gene. Target sequence 1: 59-GGACUUAACCAGUGUAGUA-39;
target sequence 2: 59-AACCAAUCCUCGACACUUA-39;target
sequence 3: 59-GCCCUACGUUUGUGAAGAA-39 and target
sequence 4: 59-CCUUAUAGAUGUAGAGAAU-39. For trans-
fection, cells were either plated on 96 well plates for MTT assays
or plated on dishes for RNA extraction. Transfections were
performed with siPORT
TM NeoFX
TM siRNA transfection reagents
(Ambion. Inc, Austin, TX) as directed by the manufacturer. The
Silencer
TM EGFP siRNA (Ambion) and siRNA ControlH reagent
(Dharmacon) were used as positive and negative controls in all
experiments. For ZNF93 inhibition, the final concentration of
siRNA was either at 25 nM or 100 nM. Media was replaced with
RPMI1640 supplemented with 10% FBS 24 hours after transfec-
tion. Total RNA was isolated after 72 hours of ZNF93 siRNA
transfection for Real-time RT-PCR confirmation.
pIRESZNF93 expression vector construction and
transfection
A 1907 base pair cDNA fragment containing the full ORF of
human ZNF93 was amplified by RT-PCR from the RNA of CS-
1/PR cell line which highly overexpresses ZNF93. RT-PCR was
performed using the sense and antisense primers to human
ZNF93: sense primer 59-ATAAGAATGCGGCCCGGAAGCC-
TAGAAATGGGACCATTG-39 to introduce a Not I site as
underlined, and antisense primer: 59-GGTGGATCCTCACAC-
TTCTAGGGTTTCT-39 ( GenBank # NM_031218 ) to
introduce a BamH I site as underlined. The introduced restriction
enzyme sites were designed for following transfection studies.
Clonetech’s (Palo Atlo, CA) mammalian expression vector
pIRESneo was used for functional expression study. The resulting
ZNF93 RT-PCR product was cloned into pCRH2.1 vector using
Invitrogen’s Original TA Cloning Kit. After sequence confirma-
tion, ZNF93 was cut from the pCRH2.1 vector, purified,
subcloned into the MCS of expression vector pIRESneo, and
subsequently sequenced to confirm the correct ORF. Expression
of ZNF93 cDNA was under the control of the pCMV.
Transfections were performed using LipofectAmine Plus reagents
(Invitrogen) as follows: approximately 5610
5 CS-1 cells were
plated into 90 millimeter tissue culture dishes and cultured
overnight. Prior to transfection, the growth medium was replaced
with serum free RPMI 1640 and cultured for three hours.
LipofectAmine reagent containing 5 mg of pIRESempty, pIR-
ESZNF93 was combined with Plus reagent and applied to the cells.
After culture for four hours, the media was replaced with RPMI
1640 containing 10% fetal bovine serum. G418 sulfate (Invitrogen)
selection (300 mg/ml) was started at 24 hours post transfection.
The selection medium was changed every 2 days. Effects of
overexpression ZNF93 on ET-743 and PM00104 were deter-
mined by MTT cytotoxicity assay.
Results
CS-1/ER, CS-1/PR cell lines are resistant to several
chemotherapeutic agents
CS-1/ER and CS-1/PR were selected from the parental cell
line, CS-1, by exposure to stepwise increases in ET-743 or
PM00104 concentrations for a period of one year. The drug
resistance phenotype was found to be stable after 14 months of
continuous culture in drugs or at least 6 months under drug-free
conditions. No significant difference between CS-1 and CS-1/ER
or CS-1/PR cells was observed in vitro cell growth (similar doubling
time) and microscopic morphology. MTT cytotoxicity analysis
shows that CS-1/ER, CS-1/PR are 10- 20 fold more resistant to
ET-743 and PM00104 as compared with the sensitive parent cell
line. The IC50-value of ET-743 in CS-1 cells was 0. 0008 mMa s
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The IC50-value of PM00104 in CS-1 cells was 0. 002 mMa s
compared to 0. 04 mM in CS-1/PR cells (20-fold resistance). In
addition, CS-1/ER and CS-1/PR exhibits resistance to cisplatin
and methotrexate but not to doxorubicin (Fig. 1).
A large number of genes are associated with ET-743 and
PM00104 resistance
Human Affymetrix Gene Chip U133 Plus 2.0 arrays were used
to examine relative RNA expression levels between CS-1, CS-1/
ER, and CS-1/PR. The expression profiles of these three
chondrosarcoma cell lines were evaluated by Genesifter. In
addition, we have submitted our microarray data to Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and
these array data have been assigned a GEO accession number
as GSE16748. We found a large number of genes had significantly
different levels of expression in CS-1/ER and CS-1/PR as
compared to CS-1. To focus on genes with only significant
changes in expression levels, we identified genes with a ten-fold or
greater change in expression levels. Using this criteria, 595 (CS-1/
ER), 498 (CS-1/PR) genes exhibited more than ten-fold
overexpression in the ET-743 and PM00104 resistant lines relative
to their expression in the sensitive parental lines (Fig. 2A). In
addition, 856 (CS-1/ER), 874 (CS-1/PR) transcripts were more
than ten-fold decreased in the resistant cell lines as compared to
controls (Fig. 2B). Changes in expression levels ranged from 10- to
Figure 1. CS-1/ER and CS-1/PR drug sensitivities. CS-1/ER, CS-1/PR and CS-1 cells were exposed to varying concentrations of drugs for 6 days.
Growth inhibition was determined by incubation with the tetrazolium dye MTT and by absorbance measurement at 490 nm. Data reflect three
replicates at each concentration.
doi:10.1371/journal.pone.0006967.g001
Figure 2. Venn diagram of genes overexpression (A), underexpression (B) in CS-1/ER, CS-1/PR as compared with CS-1. Genes over
expressed/under expressed in more than one cell line are indicated in the overlapping regions of the circles.
doi:10.1371/journal.pone.0006967.g002
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between cell lines and encoded for proteins with a wide variety of
biochemical functions. The genes identified encode for proteins
that bind DNA have catalytic activities, molecular transducer
activities, regulate transcription, transport proteins and molecules,
regulate enzymes and there are many other genes that have
limited characterization. The top 20 most highly overexpressed
and underexpressed genes in each of the resistant cell lines are
summarized in Table 1. There were seven genes overexpressed in
both CS-1/ER and CS-1/PR and one gene that underexpressed
Table 1. A list of the 20 most differentially expressed genes in CS-1/ER and CS-1/PR as compared with CS-1.
CS-1/ER vs CS-1 CS-1/PR vs CS-1
Overexpressed genes
Family with sequence similarity 9 (295) Metastasis related protein MB2 (91)
Zinc finger protein 93 (268) Transcribed locus AW190406 (89)
Thyroid adenoma associated (125) mRNA clone IMAGE:5229134 (81)
Transcribed locus AU156801 (120) Gremlin2, cystein knot superfamily (62)
Transcribed locus EMB gene (88) Translocase of inner mitochondrial (60)
Coiled-coil domain containing 144B (87) Zinc finger protein 43 (56)
Vitamin B12 binding protein (86) ESTs AV724769 (56)
ESTs AI655611 (76) ESTs AV696977 (56)
Transcribed locus AI8200854 (75) Coiled-coil domain containing 144B (55)
cDNA clone ADKA02259 (74) Transcribed locus AI8200854 (47)
Melanoma antigen family A 2 MAGE A2 (69) Transcribed locus EMB gene (46)
Zinc finger protein 568 (63) Zinc finger protein 93 (45)
Transcribed locus AW590062 (59) ESTs AI057226 (44)
ESTs H14374 (58) RAB7A, member RAS oncogene family (44)
Kinestin family member 17 (57) Thyroid adenoma associated (41)
mRNA C19orf9 (57) Serine/threonine kinase 32A (40)
Transcribed locus AA503877 (55) Multiple EGF-like-domanis 10 (39)
Zinc finger protein 43 (55) mRNA clone IMAGE:4670253 (39)
ESTs AI061288 (53) Dpy-19-like 2 (39)
Glutamate receptor AMPA4 (48) ESTs AI655611 (39)
Underexpressed genes
Phosphoglucomutase 5 (470) Sperm proein AF098306 (535)
Deleted in azoospermia 1 (366) Sperm proein NM-013453 (412)
Biglycan AA845258 (319) Lung type-1 cell membrane glycoprotein (127)
Transcribed locus BC015772 (313) Deleted in axoospermina 2 (110)
Collagen, type III, alpha AI813758 (176) cDNA clone IMAGE:4791911 (109)
mRNA clone FLC1492 (166) Cartilage glycoprotein-39 (108)
ATP-binding cassette, sub-family G 1 (150) ESTs AI758697 (94)
Biglycan NM_001711 (147) Cancer/testis antigen 1A (88)
Cartilage gycoprotein-39 (139) cDNA clone FLJ38810(83)
Collagen, type III, alpha AU144167 (134) Cancer/testis antigen 2 (80)
Keltch domain containing 1 (124) Transcribed locus AI651510 (78)
cDNA FLJ43080 (107) cDNA FLJ11909 (73)
Fibrillin 2 (101) Cadherin 3, type 1 (66)
Odd Ox/ten-m homolog 2 (100) Cancer/testis antigen 1A (72)
Transcribed locus AI384053 (87) mRNA regulated in glioma (63)
Optineurin (86) Regulatory factor X, 3 (61)
cDNA FLJ14388 (86) Fibrillin 2 (58)
cDNA clone RP4-76112 (74) thymic stromal lymphopoietin (58)
Chemokine ligand 3 (71) EPH receptor A4 (55)
Phosphoglucomutase 5 (70) Sulfatase 2 (46)
Genes in bold type are differentially expressed in both two resistant cell lines. The number in parentheses following the gene name is the fold overexpression/
underexpression compared to the respective sensitive cell line.
doi:10.1371/journal.pone.0006967.t001
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over-lapping gene in the top 20 over expressed genes list as
compared to the under expressed genes list. We also noticed the
degree of change in gene expression was more dramatic in the set
of under expressed genes (Table 1).
Genes differentially expressed in both resistant cell lines
Fig. 2 Venn diagram shows that 185 genes were overexpressed,
174 genes were underexpressed in the both CS-1/ER, and CS-1/
PR resistant cell lines in comparison to CS-1 (Fig. 2A and Fig. 2B).
The top 20 most highly overexpresssed genes in both resistant cell
lines are summarized in Table 2. As 3 out top 20 overecpressing
genes in both CS-1/ER, and CS-1/PR resistant cell lines are zinc
finger protein genes (ZNF93, ZNF43 and ZNF568), we decided to
further validate these genes by real-time RT-PCR.
TaqMan real-time RT-PCR analysis of differentially
expressed genes
To validate the array data, we performed Real-Time RT-PCR
of three genes that were differentially expressed in the two resistant
cell lines. ZNF93, ZNF43, and THADA RNA expression were
measured by TaqMan RNA assay kit. Differential expression of
ZNF93 and ZNF43 were confirmed in both CS-1/ER and CS-1/
PR resistant cell lines (Fig. 3A, Fig. 3B and Fig. 3C). THADA
overexpression was not confirmed in resistant cell line CS-1/ER
(Fig. 3D).
Expression of ZNF93 in other multidrug resistant cell
lines
ZNF93 gene overexpressed in both CS-1/ER and CS-1/PR cell
lines and the function of ZNF93 is unclear although the protein
has been implicated in the cellular transcriptional regulation. As
ZNF93 gene has not previously been linked to drug resistance and
was selected for further study. We further evaluated the expression
of ZNF93 in other multidrug resistant cell lines by real-time RT-
PCR. The results demonstrated that ZNF93 is overexpressed in
two ET-743 resistant Ewing sarcoma cell line, TC-ET, as well as
in a cisplatin resistant ovarian cancer cell line, A2780cp, as
compared with their ET-743 or cisplatin sensitive parental cell
lines, but ZNF93 was not overexpressed in paclitaxel resistant cell
lines SKOV-3TR and MCF-7TR (Fig. 4).
Effects of inhibition of ZNF93 expression by siRNA on
drug sensitivities
To determine whether ZNF93 plays a role in ET-743 and
PM00104 sensitivity, we inhibited its expression in CS-1/PR cells
using siRNA knockdown. The relative drug sensitivities were
evaluated by comparison of IC50 values determined by MTT in
siRNA-treated, non-specific siRNA-treated and non-treated con-
trol multidrug resistant cell lines. First, cytotoxicity to ET-743 and
PM00104 was measured 4 days after transfection of resistant cells
with ZNF93 siRNA oligos from Applied Biosystems. We observed
that ZNF93 down-regulation did partially recover sensitivity to
PM00104 (Fig. 5A) in CS-1/PR cell line. Real time RT-PCR
revealed ZNF93 expression was significantly decreased after the
cells treated with siRNA (Fig. 5B). Similar results were found in
drug resistant cell line CS-1/ER (Data not shown). In addition, for
validation of ZNF93 RNAi specificity, the siGenome SMARTpool
Human ZNF93 siRNAs were purchased from Dharmacon with
the four target sequences of ZNF93 gene and tested in cisplantin
resistant cell line A2780cp. The expression ZNF93 in siRNA
transfected A2780cp cells was significantly decreased as evaluated
by Real-Time RT-PCR (Fig. 5D). MTT assay showed the IC50
Table 2. Top 20 overexpressed genes (.10 fold) in both CS-1/ER and CS-1/PR resistant cell lines.
Gene name GenBank accession no Chromosome location Function
Family with sequence similarity 9 AF494344 Xp22 unknown
Zinc finger protein 93* BC020837 19p12 transcriptional regulation
Thyroid adenoma associated BC037990 2p21 unknown
Coiled-coil domain containing 144B AL162091 17p11 transcriptional regulation
Transcribed locus EMB Gene BE080109 5q11 regulator of cell/ECM interactions
Clone IMAGE:5229134 mRNA BC037976 13p11 unknown
Transcribed locus AU156801 1p17 unknown
Transcribed locus AI820854 14p16 unknown
ESTs AI655611 1p11 unknown
Zinc finger protein 43 AK022905 19p13 transcriptional regulation
Metastasis related protein (MB2) AF100640 unknown unknown
Translocase of inner mitochondrial BC005236 Xq22 chaperone-like protein
Transcribed locus AW190406 7p7 unknown
Vitamin B12 binding protein NM_001062 11q11 transports cobalamin into cells
ESTs AV724769 3p8 unknown
Zinc finger protein 568 BC031218 19q13 transcriptional regulation
Clone ADKA02259 AK024520 2p18 unknown
Dpy-19-like 2 AA758751 7p14 unknown
Chromosome 19 ORF 9 (C19orf9) NM_152659 unknown unknown
Transcribed locus AA503877 1p11 unknown
*Genes in bold were chosen for real-time RT-PCR validation.
doi:10.1371/journal.pone.0006967.t002
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with the untreated resistant lines (Fig. 5C), suggesting that ZNF93
siRNA inhibits ZNF93 expression and partially restores the
sensitivity of the resistant cell line to cisplatin.
Effects of overexpression of ZNF93 on ET-743, PM00104
and cisplatin sensitivities
Our analyses of endogenous ZNF93 expression demonstrated
that ZNF93 is frequently upregulated in ET-743, PM00104 and
cisplatin multiple drug resistant cancer cell lines, ZNF93 down-
regulation by siRNA could partially recover sensitivity to ET-
743,PM00104 and cispatin. These results suggest that the ZNF93
protein may be critically involved in the development of resistance
to these drugs. To further determine whether ZNF93 directly
participates in the establishment of the resistant phenotype, we
transfected the ET-743 and PM00104 sensitive cell line CS-1 with
a ZNF93 expression vector and generated stable cell line which
overexpress ZNF93 (Figure 6D). We then asked if exogenous
overexpression of ZNF93 was sufficient to confer increased ET-
743 and PM00104 resistance. The results from the MTT assay in
the tranfected cell lines are shown in Fig. 6. ZNF93 transfected
CS-1 cells are relatively resistant to ET-743, PM00104 and
cisplatin, whereas no significant change in resistance was observed
in CS-1 cells transfected with the empty vector (Figure 6A to C).
Figure 3. TaqMan real-time RT-PCR evaluates the differentially expressed genes. A: Amplification plot for b-actin gene. B: Amplification
plot for ZNF93 gene. C: Relative expression levels of ZNF93 mRNA. D: Summary of relative expression levels of ZNF93, ZNF43 and THADA mRNA.
doi:10.1371/journal.pone.0006967.g003
Figure 4. ZNF93 mRNA expression in multiple multi drug
resistant cell lines by real-time RT-PCR. All real-time RT-PCR data
have been normalized to b-actin.
doi:10.1371/journal.pone.0006967.g004
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by real-time RT-PCR (Fig. 6D).
Discussion
Results from several clinical trials suggest that ET-743 has
antitumor activity against several cancer types, including soft tissue
sarcomas, breast cancer, and ovarian cancer [2,3]. Patients with
advanced ovarian and breast cancer as well as bone or soft tissue
sarcomas typically undergo several lines of anti-cancer regimens
before ultimately succumbing to their disease. Multidrug resistance
is thought to play an important role in the inevitable failure of
tumors to respond to each successive line of chemotherapy.
Therefore, understanding the patterns and mechanisms of cross-
resistance and finding ways to overcome it is an important goal.
Several studies have studied the mechanisms of ET-743 drug
resistance with different approaches. However, contradictory
results have been published from various groups attempting to
correlate resistance to different expression levels of RNAs and
proteins in resistant cells [9,10,13,14,21]. Further resolution of the
differences among these results might be best facilitated by
genome-wide transcriptional array analysis.
In this study, we report successful establishment of two
chondrosarcoma cell lines resistant to ET-743 or PM00104. We
then asked how the gene expression levels related to differences in
drug resistance in these two cell lines. We used Affymetrix Gene
Chip U133 Plus 2 to examine genome-wide expression of RNA
transcripts. As compared with several studies using smaller scale
gene array, this array completely covers the entire human genome
with over 47,000 transcripts. We validated the gene array results
for the genes with the most significant changes with real-time RT-
PCR. As expected, there are a large number of transcriptional
changes associated with in vitro acquired resistance to ET-743 and
PM00104. Indeed, about 5% to 10% (with cut off value of 2 fold)
of transcripts are over-expressed or under-expressed in the
resistant cell lines CS-1/ER and CS-1/PR as compared to the
sensitive parental cell line.
In the list of top 20 over expressing genes for both CS-1/ER
and CS-1/PR, the same three zinc finger protein genes, ZNF93,
ZNF43 and ZNF568 (Table 2) were all identified. These genes
have not been previously associated with drug resistance. Real-
time PCR confirmed ZNF93 and ZNF43 are consistently over
expressed in these resistant cell lines (Fig. 3). Preliminary
evaluation of ZNF93 confirms that its expression is associated
Figure 5. Effect of ZNF93 inhibition on drug sensitivity in CS-1/PR and A2780cp cells. A: CS-1/PR was transfected with ZNF93
siRNA*(Applied Biosystems) as well as non-specific siRNA. C: A2780cp was transfected with ZNF93 siRNA
{ (Dharmacon) as well as non-specific siRNA.
The relative sensitivity of each treatment to PM00104 or cisplatin was determined by MTT analysis 72 hours post-transfection . B and D: Confirmation
of ZNF93 knockdown by real-time RT-PCR. Total RNA was isolated 72 hours post-transfection and ZNF93 expression was analyzed by real-time
RT-PCR.
doi:10.1371/journal.pone.0006967.g005
ZNF93 and ET-743 Resistance
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6967with the multidrug-resistant phenotype in additional cell lines.
ZNF93 gene expression was also shown to be increased in ET-743
resistant Ewing’s sarcoma cell line (TC-ET) and in the cisplatin-
resistant ovarian cancer cell line (A2780cp) but not in the
paclitaxel resistant cell lines (SKOV-3TR) nor in the paclitaxel
resistant breast cancer cell line (MCF-7TR), suggesting a
fundamentally different mechanism for paclitaxel resistance from
ET-743 or PM00104 resistance.
Functional analysis of ZNF93 provides some insight into the
epigenetics of ET-743 and PM00104 resistance and might be of
use in revealing targets for overcoming drug resistance. Inhibition
of ZNF93 using siRNA could partially reverse PM00104, ET-743
and cisplatin resistance in CS-1/PR and A2780cp cells (Fig. 5A).
Importantly, overexpression of the ZNF93 protein in a PM00104
and ET-743 sensitive chondrosarcoma cell line CS-1 led to a
modest level of PM00104, ET-743 and cisplatin resistance
implying an important role for ZNF93 in the development of
the drug-resistant phenotype. Other zinc finger proteins such as
ZNF143 have been shown to be associated with cisplatin
resistance, and ZNF143 depletion using siRNA confers cell
sensitivity to cisplatin, but not to oxaliplatin, etoposide and
vincristine [23,24]. ZNF143 has been found associated with
tumor suppressor gene p73 but not with p53 expression.
Interestingly, p73 could stimulate the binding of ZNF143 to
cisplatin-modified DNA. Both Rad51 and flap endonuclease-1
are overexpressed in cisplatin-resistant cells and are target genes
of ZNF143[23,24,25]. These results suggest ZNF93, ZNF143 as
well as other zinc finger proteins may be involved uniquely in
DNA repair pathway following DNA damage by ET-743,
PM00104, and cisplatin. Future studies on identification of
potential ZNF93 target genes for DNA repair pathways are
needed to fully understand the molecular mechanism of ZNF93
overexpressin in multidrug resistant cells. Despite its potential role
in the transcriptional regulation and DNA repair, ZNF93 may
have a potential as an novel target for anticancer therapeutic
development. There were reports that defects in the DNA
mismatch repair pathway, usually associated with increased
resistance to methylating agents and cisplatin, did not affect the
cytotoxic activity of ET-743. However, ET-743 did show
decreased activity (from 2- to 8-fold) in nucleotide excision repair
(NER)-deficient cell lines compared to NER-proficient cell
lines [26,27].
Figure 6. Exogenous expression of ZNF93 confers PM00104, ET743 resistance. A, B and C: Relative cytotoxicity of ET-743,PM00104 and
cisplatin in CS-1 derived cell lines (CS-1/pIRESZNF93) stably transfected with a pIRESZNF93 expression vector and in the parental (CS-1) and empty vector
(CS-1/pIRES) controls were assessed using the MTT assay. All samples were analyzed in triplicate. D: Confirmation of ZNF93 overexpression in
pIRESZNF93 tranfected CS-1 cells by real-time RT-PCR as described in Materials and Methods.
doi:10.1371/journal.pone.0006967.g006
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PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e6967It is obvious that cell lines are not fully representative of tumors
from patients, but they do have the advantages of reproducibility,
availability, and homogeneity in cell lineage. Further studies on
tumor samples to correlate the levels of zinc finger protein such as
ZNF93 and DNA repair genes with clinical data will further clarify
the biochemical roles of these proteins and their potential as
therapeutic targets. The observations described here on gene
expression in ET-743 and PM00104 resistant chondrosarcoma cell
lines may provide the basis for such future studies.
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